The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close ...

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint)Statistically ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

The U.S. FDA approved 15 drugs in October ... exceeding last year’s average of 16, 2022’s 12.5, and the 17-per-month averages recorded in both 2021 and 2020.

FDA approval for acoramidis was based on the ATTRibute-CM trial, in which the drug met the 30-month primary ... 30-day all-cause mortality or 6MWD at 12 months with acoramidis, as ATTRibute ...

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

After months of uncertainty and controversy, the FDA has given approval to Sarepta's Duchenne muscular dystrophy drug – even though it hasn't yet shown any proof it can slow progress of the ...

Despite its findings, the FDA will not update the drug's label based on the presented data. USA TODAY has reached out to the FDA for comment. The brain receptors that the drug is binding to are ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.Cmvv_fHs.js ...